𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia

✍ Scribed by L. Otero; M. H Ornellas; J. Dobbin; T. De Souza Fernandez

Book ID
111415042
Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
52 KB
Volume
30
Category
Article
ISSN
1751-5521

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Effects of age on prognosis with imatini
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia
✍ Jorge Cortes; Moshe Talpaz; Susan O'Brien; Francis Giles; Mary Beth Rios; Jianqu πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 121 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Older age is a consistent poor prognostic factor in patients with Philadelphia chromosome (Ph)‐positive chronic myelogenous leukemia (CML). Whether this is related to an intrinsic worse disease biology or to inadequate drug delivery or excessive treatment‐associated toxic

Analysis of the impact of imatinib mesyl
Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome–positive chronic myelogenous leukemia treated with interferon-Ξ± regimens for early chronic phase
✍ Hagop Kantarjian; Susan O'Brien; Jorges Cortes; Jianqin Shan; Francis Giles; Gui πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 106 KB πŸ‘ 1 views

## Abstract ## BACKGROUND The effect on prognosis of adding imatinib mesylate to the treatment of patients with Philadelphia chromosome (Ph)‐positive chronic myelogenous leukemia (CML) has not been explored fully. The objective of the current study was to evaluate the benefit of adding imatinib to